Following its tie-up with Ranbaxy, pharma major GlaxoSmithKline said on Friday it was open to partnership with other Indian companies in the field of drug discovery and development, but it must be allowed to import molecules for research.
The Sensex opened with a positive gap of 20 points at 10,133.
The Sensex finished 38 points higher at 3,640 on Thursday. The Nifty closed with a gain of 12 points at 1,146.
Competition in the US pharmaceutical market swelled in recent years, with increasing generic penetration.
The Sensex opened with a negative gap of 19 points at 6,896, but soon touched a high of 6,955 in early deals.
Top ten billionaires in India.
The Sensex opened with a positive gap of 11 points at 5,381, it slipped marginally to touch an intra-day low of 5,380.
The 30-share Sensex ended 50 points lower at 28,112 and the 50-share Nifty declined 12 points to close at 8,531.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
Inspections only in domestic authorities' presence, visiting US drug regulator told
Shanghvi needs to deploy this excess cash.
Markets closed the day in green on favourable domestic factors,
And when an inspector asked about the contents of unlabelled vials in the laboratory glassware washing area, a plant worker dumped them down a sink and said the contents could not be determined, according to a July 18 letter from the US Food and Drug Administration to Wockhardt, which makes sterile injectable drugs and various forms of insulin.
The S&P BSE Sensex has rallied about 28 per cent in 2014, after formation of a stable government at the Centre.
The year 2015 will be a tough year for mergers and acquisition.
The Sensex took less than two years to rally from the 10,000-mark it first hit in February 2006 to double that on that New Year's Eve.
An International Policy Network report in 2010 found that seven per cent of drugs bought from wholesale traders were substandard, and 3.6 per cent of the drugs from traders contained no active ingredient whatsoever.
The 30-share Sensex ended down 224 points at 28,442 and the 50-share Nifty ended down 101 points at 8,606.
US will remain a growth driver, with launches & existing portfolios set to result in 15% growth for FY15.
Combined net profit estimated to grow 14.6% year-on-year, against a 5.7% decline in the Dec 2015 quarter
According to Munjal, there is an opportunity for somebody who comes from a not for profit background in health care to do something.
Roadblocks ahead as these medicines could face new clinical tests, more scrutiny
The 30-share Sensex provisionally ended up 112 points at 28,555 and the 50-share Nifty closed 24 points higher at 8,561 after hitting a record high of 8,626.95.
This is to take head on big American pharmaceutical giants, which in the recent past had launched a strong anti-India campaign against efforts of such companies to provide affordable health care not only to people in India, but also in the third world countries.
The 30-share Sensex ended up 292 points at 29,571 and the 50-share Nifty closed up 75 points at 8,910.
Sensex, Nifty put up a good show in closing trade.
The National Pharmaceutical Pricing Authority will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according to official sources.
Benchmark indices finished higher on hopes of economic reforms
Who is to take their place? Will a new generation of entrepreneurs start up with better business sense, or at least better luck? But the so-called unicorns are mostly copy-cat entrepreneurs whose cash flow is funded by overseas (including Chinese) money, notes T N Ninan.
A global policy would reward firms which strive for higher quality.
A probe finds several pharma majors in breach of the law; and in turn they blame the government.
Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.
The country's drug companies have attracted the highest number of enforcements from the American drug regulator in 2013, a year that has seen the US Food and Drug Administration turning stricter to ensure compliance levels and quality of medicines.
Select metal stocks rebounded while power stocks extended losses after SC verdict on coal block allocations.
The Sensex ended down 251 points at 27,351 and the Nifty shed 65 points to close at 8,228.
BSE Midcap and Smallcap indices ended in line with their larger counterparts and closed marginally up 0.2% and 0.4%, each
The top gainers on the Sensex were Cipla, Bharti Airtel, Maruti Suzuki, Hero Moto & Sesa Sterlite.
Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
Top companies added employees at 3% CAGR from 2003-04 to 2013-14, while revenues grew at 18%.
At 15.05 PM, the 30-share Sensex was up 281 points at 28,238 and the 50-share Nifty gained 86 points at 8,577
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances